Invasive Treatment Strategy in Adults With Frailty and Non–ST-Segment Elevation Myocardial Infarction
JAMA Network Open · 2024
DOI: 10.1001/jamanetworkopen.2024.0809 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, 2024. Verfasst von Juan Sanchis und 25 weiteren Autor:innen. Beteiligte Einrichtung: Cardiology Department, University Clinic Hospital of València, University of València, Instituto de Investigación Sanitaria Clínico Valencia, Centro …. Hauptthemen laut MEDLINE: Frailty, Non-ST Elevated Myocardial Infarction, ST Elevation Myocardial Infarction. Die Arbeit wurde bisher 31-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Gerontologische Pflege
Abstract (Originalsprache)
Importance The MOSCA-FRAIL randomized clinical trial compared invasive and conservative treatment strategies in patients with frailty with non–ST-segment elevation myocardial infarction (NSTEMI). It showed no differences in the number of days alive and out of the hospital at 1 year.
Objective
To assess the outcomes of the MOSCA-FRAIL trial during extended follow-up. Design, Setting, and Participants The MOSCA-FRAIL randomized clinical trial was conducted at 13 hospitals in Spain between July 7, 2017, and January 9, 2021, and included 167 adults (aged ≥70 years) with frailty (Clinical Frailty Scale score ≥4) and NSTEMI. In this preplanned secondary analysis, follow-up was extended to January 31, 2023. Data analysis was performed from April 5 to 29, 2023, using the intention-to-treat principle.
Interventions
Patients were randomized to a routine invasive (coronary angiography and revascularization if feasible [n = 84]) or a conservative (medical treatment with coronary angiography only if recurrent ischemia [n = 83]) strategy. Main outcomes and measures The primary end point was the difference in restricted mean survival time (RMST). Secondary end points included readmissions for any cause, considering recurrent readmissions.
Results
Among the 167 patients included in the analysis, the mean (SD) age was 86 (5) years; 79 (47.3%) were men and 88 (52.7%) were women. A total of 93 deaths and 367 readmissions accrued. The RMST for all-cause death over the entire follow-up was 3.13 (95% CI, 2.72-3.60) years in the invasive and 3.06 (95% CI, 2.84-3.32) years in the conservative treatment groups. The RMST analysis showed inconclusive differences in survival time (invasive minus conservative difference, 28 [95% CI, −188 to 230] days). Patients under invasive treatment tended to have shorter survival in the first year (−28 [95% CI, −63 to 7] days), which improved after the first year (192 [95% CI, 90-230] days). Kaplan-Meier mortality curves intersected, displaying higher mortality to 1 year in the invasive group that shifted to a late benefit (landmark analysis hazard ratio, 0.58 [95% CI, 0.33-0.99]; P = .045). Early harm was more evident in the subgroup with a Clinical Frailty Scale score greater than 4. No differences were found for the secondary end points. Conclusions and Relevance In this extended follow-up of a randomized clinical trial of patients with frailty and NSTEMI, an invasive treatment strategy did not improve outcomes at a median follow-up of 1113 (IQR, 443-1441) days. However, a differential distribution of deaths was observed, with early harm followed by later benefit. The phenomenon of depletion of susceptible patients may be responsible for this behavior.
Trial registration
ClinicalTrials.gov Identifier: NCT03208153
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Cardiology Department, University Clinic Hospital of València, University of València, Instituto de Investigación Sanitaria Clínico Valencia, Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares (CIBERC…
- Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain.
- Cardiology Department, Universisty Hospital 12 de Octubre and Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), CIBERCV, Madrid, Spain.
- Complutense University, Madrid, Spain.
- Cardiology Department, University Hospital of Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain.
- Central Defense Hospital, Alcalá University, Madrid, Spain.
Zitieren
APA
Sanchis, J., Bueno, H., García-Blas, S., Alegre, O., Martí, D., Martínez-Sellés, M., Domínguez-Pérez, L., Díez-Villanueva, P., Barrabés, J. A., Marín, F., Villa, A., Sanmartín, M., Llibre, C., Sionís, A., Carol, A., Fernández-Cisnal, A., Calvo, E., Morales, M. J., Elízaga, J., …, & Ariza-Solé, A. (2024). Invasive Treatment Strategy in Adults With Frailty and Non–ST-Segment Elevation Myocardial Infarction. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2024.0809
Vancouver
Sanchis J, Bueno H, García-Blas S, Alegre O, Martí D, Martínez-Sellés M, et al. Invasive Treatment Strategy in Adults With Frailty and Non–ST-Segment Elevation Myocardial Infarction. JAMA Network Open. 2024. doi:10.1001/jamanetworkopen.2024.0809
BibTeX
@article{Sanchis2024,
author = {Sanchis, Juan and Bueno, Héctor and García-Blas, Sergio and Alegre, Oriol and Martí, David and Martínez-Sellés, Manuel and Domínguez-Pérez, Laura and Díez-Villanueva, Pablo and Barrabés, Jose A and Marín, Francisco and Villa, Adolfo and Sanmartín, Marcelo and Llibre, Cinta and Sionís, Alessandro and Carol, Antoni and Fernández-Cisnal, Agustín and Calvo, Elena and Morales, María José and Elízaga, Jaime and Gómez, Iván and Alfonso, Fernando and García Del Blanco, Bruno and Formiga, Francesc and Núñez, Eduardo and Núñez, Julio and Ariza-Solé, Albert},
title = {Invasive Treatment Strategy in Adults With Frailty and Non–ST-Segment Elevation Myocardial Infarction},
journal = {JAMA Network Open},
year = {2024},
doi = {10.1001/jamanetworkopen.2024.0809}
}
EUVIMED